Positive Phase III data for Lupin's trichomoniasis candidate

5 May 2020

India’s Lupin (BSE: 500257) has announced positive top-line results from its pivotal Phase III clinical trial to assess efficacy and safety of single-dose Solosec (secnidazole) 2g oral granules in 147 female patients with trichomoniasis.

Solosec came into Lupin’s portfolio via its October 2017 acquisition of Symbiomix Therapeutics for around $200 million, and the drug gained US Food and Drug Administration for the treatment of bacterial vaginosis (BV) in adult women in May that year.

The trial demonstrated a clinically- and statistically-significant response rate, or microbiological cure, in patients dosed with Solosec as compared to placebo (p<0.001), with the news sending Lupin’s shares up 2.57 to 862.70 rupees yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical